ZA200405246B - Use of 4-oxobutanoic acid derivatives in the treatnent of inflammation. - Google Patents
Use of 4-oxobutanoic acid derivatives in the treatnent of inflammation. Download PDFInfo
- Publication number
- ZA200405246B ZA200405246B ZA200405246A ZA200405246A ZA200405246B ZA 200405246 B ZA200405246 B ZA 200405246B ZA 200405246 A ZA200405246 A ZA 200405246A ZA 200405246 A ZA200405246 A ZA 200405246A ZA 200405246 B ZA200405246 B ZA 200405246B
- Authority
- ZA
- South Africa
- Prior art keywords
- oxobutanoic acid
- substance
- composition
- benzyl
- chosen
- Prior art date
Links
- 230000004054 inflammatory process Effects 0.000 title claims description 20
- 206010061218 Inflammation Diseases 0.000 title claims description 19
- UIUJIQZEACWQSV-UHFFFAOYSA-N succinic semialdehyde Chemical class OC(=O)CCC=O UIUJIQZEACWQSV-UHFFFAOYSA-N 0.000 title claims description 14
- 239000000126 substance Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- -1 cyano, hydroxyl Chemical group 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 230000007170 pathology Effects 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000008035 Back Pain Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 208000008930 Low Back Pain Diseases 0.000 claims description 3
- 206010054805 Macroangiopathy Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 206010036030 Polyarthritis Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 206010062198 microangiopathy Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 3
- 238000002636 symptomatic treatment Methods 0.000 claims description 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000005936 piperidyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- DZRBTTWGDHUKDS-UHFFFAOYSA-N 2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid Chemical compound C=1C=CC=CC=1CC(C(=O)O)CC(=O)C1=CC=C(F)C=C1 DZRBTTWGDHUKDS-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0115601A FR2832925B1 (fr) | 2001-12-03 | 2001-12-03 | Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200405246B true ZA200405246B (en) | 2005-06-24 |
Family
ID=8870049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200405246A ZA200405246B (en) | 2001-12-03 | 2004-07-01 | Use of 4-oxobutanoic acid derivatives in the treatnent of inflammation. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7897644B2 (fr) |
| EP (1) | EP1450780B1 (fr) |
| JP (1) | JP2005511654A (fr) |
| KR (1) | KR20050043728A (fr) |
| CN (1) | CN1599604A (fr) |
| AT (1) | ATE355834T1 (fr) |
| AU (1) | AU2002342883B2 (fr) |
| BR (1) | BR0214644A (fr) |
| CA (1) | CA2468910C (fr) |
| DE (1) | DE60218726T2 (fr) |
| ES (1) | ES2280589T3 (fr) |
| FR (1) | FR2832925B1 (fr) |
| HU (1) | HUP0402242A3 (fr) |
| MX (1) | MXPA04005265A (fr) |
| PL (1) | PL369845A1 (fr) |
| RU (1) | RU2004120557A (fr) |
| TW (1) | TW200300670A (fr) |
| WO (1) | WO2003047561A1 (fr) |
| ZA (1) | ZA200405246B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009071161A1 (fr) | 2007-12-03 | 2009-06-11 | Merck Patent Gmbh | Utilisation de dérivés de l'acide 4-oxobutanoïque dans le traitement de pathologies associées à des troubles immunologiques |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3784701A (en) * | 1970-09-21 | 1974-01-08 | American Cyanamid Co | Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain |
| JPS59144717A (ja) * | 1983-02-07 | 1984-08-18 | Microbial Chem Res Found | 鎮痛剤 |
| US5789434A (en) * | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
| GB9522615D0 (en) * | 1995-11-03 | 1996-01-03 | Pharmacia Spa | 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity |
| CO5011113A1 (es) * | 1996-05-15 | 2001-02-28 | Bayer Corp | Derivados de acido 3-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz y composiciones farmaceuticas que los contienen |
| FR2752422B1 (fr) * | 1996-08-16 | 1998-11-06 | Lipha | Composition pharmaceutique contenant des acides 4-oxo-butanoiques |
| FR2777566B1 (fr) * | 1998-04-15 | 2003-02-21 | Synthelabo | Derives d'azacycloalcanes, leur preparation et leur application en therapeutique |
| US6060250A (en) * | 1998-06-30 | 2000-05-09 | Incyte Pharmaceuticals, Inc. | Human transferases |
| WO2000006560A1 (fr) * | 1998-07-30 | 2000-02-10 | Warner-Lambert Company | Composes heteroaromatiques tricycliques et leurs derives utilises comme inhibiteurs des metalloproteinases matricielles |
| FR2793411B1 (fr) * | 1999-05-11 | 2001-06-29 | Synthelabo | Utilisation de derives de l'acide succinique pour obtenir un medicament destine au traitement de l'inflammation |
| CA2401356A1 (fr) * | 2000-02-24 | 2001-08-30 | Takeda Chemical Industries, Ltd. | Medicament combine |
-
2001
- 2001-12-03 FR FR0115601A patent/FR2832925B1/fr not_active Expired - Fee Related
-
2002
- 2002-11-06 DE DE60218726T patent/DE60218726T2/de not_active Expired - Lifetime
- 2002-11-06 PL PL02369845A patent/PL369845A1/xx unknown
- 2002-11-06 ES ES02779532T patent/ES2280589T3/es not_active Expired - Lifetime
- 2002-11-06 RU RU2004120557/15A patent/RU2004120557A/ru not_active Application Discontinuation
- 2002-11-06 HU HU0402242A patent/HUP0402242A3/hu unknown
- 2002-11-06 AT AT02779532T patent/ATE355834T1/de not_active IP Right Cessation
- 2002-11-06 CA CA2468910A patent/CA2468910C/fr not_active Expired - Fee Related
- 2002-11-06 CN CNA028241045A patent/CN1599604A/zh active Pending
- 2002-11-06 JP JP2003548817A patent/JP2005511654A/ja not_active Ceased
- 2002-11-06 EP EP02779532A patent/EP1450780B1/fr not_active Expired - Lifetime
- 2002-11-06 US US10/497,491 patent/US7897644B2/en not_active Expired - Fee Related
- 2002-11-06 AU AU2002342883A patent/AU2002342883B2/en not_active Ceased
- 2002-11-06 KR KR1020047006346A patent/KR20050043728A/ko not_active Application Discontinuation
- 2002-11-06 WO PCT/EP2002/012357 patent/WO2003047561A1/fr active IP Right Grant
- 2002-11-06 BR BR0214644-4A patent/BR0214644A/pt not_active IP Right Cessation
- 2002-11-06 MX MXPA04005265A patent/MXPA04005265A/es unknown
- 2002-11-29 TW TW091134839A patent/TW200300670A/zh unknown
-
2004
- 2004-07-01 ZA ZA200405246A patent/ZA200405246B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60218726D1 (de) | 2007-04-19 |
| EP1450780B1 (fr) | 2007-03-07 |
| US20050014768A1 (en) | 2005-01-20 |
| PL369845A1 (en) | 2005-05-02 |
| CA2468910C (fr) | 2012-01-03 |
| BR0214644A (pt) | 2004-11-03 |
| TW200300670A (en) | 2003-06-16 |
| AU2002342883A1 (en) | 2003-06-17 |
| US7897644B2 (en) | 2011-03-01 |
| FR2832925B1 (fr) | 2006-07-14 |
| CA2468910A1 (fr) | 2003-06-12 |
| FR2832925A1 (fr) | 2003-06-06 |
| KR20050043728A (ko) | 2005-05-11 |
| AU2002342883B2 (en) | 2007-11-29 |
| JP2005511654A (ja) | 2005-04-28 |
| RU2004120557A (ru) | 2005-05-10 |
| HUP0402242A3 (en) | 2006-01-30 |
| EP1450780A1 (fr) | 2004-09-01 |
| WO2003047561A1 (fr) | 2003-06-12 |
| CN1599604A (zh) | 2005-03-23 |
| DE60218726T2 (de) | 2007-11-15 |
| MXPA04005265A (es) | 2004-10-11 |
| HUP0402242A2 (hu) | 2005-02-28 |
| ES2280589T3 (es) | 2007-09-16 |
| ATE355834T1 (de) | 2007-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0674511B1 (fr) | Compositions antipyretiques et analgesiques contenant du r-cetrolac optiquement pur | |
| DE69532216D1 (de) | 1-Acetyl-5-Bromo-4,6-Dimethylindolin | |
| DE122006000051I1 (de) | Ester der 5-Aminolevulins{ure als Mittel zur Photosensibillisierung in der Chemotherapie | |
| RU2007148994A (ru) | Композиции и способы лечения заболевания сетчатки | |
| KR20090129994A (ko) | 고지혈증 예방 및/또는 치료제 | |
| AU2005237543B2 (en) | Statins for the treatment of ocular hypertension and glaucoma | |
| CA2468910C (fr) | Utilisation de derives de l'acide 4-oxobutanoique pour le traitement d'inflammations | |
| RU2006104024A (ru) | Каппа-агонисты, в особенности для лечения и/или профилактики синдрома раздраженной толстой кишки | |
| WO2012162063A1 (fr) | Compositions administrables par voie orale comprenant des insaponifiables d'avocat/de graines de soja et de l'acide lipoïque, et procédés d'administration | |
| KR950701929A (ko) | 비정상적인 칼슘 및 인산염 대사를 치료하기 위한 황-함유 포스포네이트 화합물(sulfur-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism) | |
| JPH06500537A (ja) | アテローム硬化症の治療のためのアリールヒドロキシ尿素化合物の使用 | |
| AU2016381152A1 (en) | Indolizine derivatives, composition and methods of use | |
| EP1448181A1 (fr) | Composition pharmaceutique contenant une combinaison de metformine et d'un acide 4-oxobutanoique et son utilisation pour traiter le diabete | |
| AU657490B2 (en) | 5-(2-chloro-1-hydroxyethyl)-4-methylthiazole | |
| JP2012193146A (ja) | がん化学療法誘発脱毛に対する抗脱毛用組成物 | |
| AU2572400A (en) | Intermittent claudication therapeutic drugs comprising pyrroloazepines | |
| RU2004123253A (ru) | Фармацевтическая композиция, содержащая ингибитор альфа-глюкозидазы и 4-оксобутаноевую кислоту, и ее применение для лечения диабета | |
| DE69503760T2 (de) | Kaliumsalz eines biphenylmethanderivates und dasselbe enthaltendes medikament | |
| WO2003047574A1 (fr) | Composition pharmaceutique renfermant un derive de type 5-phenoxyalkyl-2,4-thiazolidinedione et un acide 4-oxobutanoique | |
| WO2003057216A1 (fr) | Composition pharmaceutique contenant une glitazone et un acide 4-oxobutanoique, et utilisation de cette composition dans le traitement du diabete |